These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10959714)

  • 21. A simple assay for human factor IX: use of canine hemophilia B plasma as substrate.
    Goldsmith JC; Chung KS; Roberts HR
    Thromb Res; 1978 Mar; 12(3):497-502. PubMed ID: 653637
    [No Abstract]   [Full Text] [Related]  

  • 22. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
    Osterud B; Kasper CK; Prodanos C
    Thromb Res; 1979; 15(1-2):235-43. PubMed ID: 483278
    [No Abstract]   [Full Text] [Related]  

  • 23. Polymorphism of normal factor IX detected by mouse monoclonal antibodies.
    Wallmark A; Ljung R; Nilsson IM; Holmberg L; Hedner U; Lindvall M; Sjögren HO
    Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3839-43. PubMed ID: 3873655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
    Xu L; Gao C; Sands MS; Cai SR; Nichols TC; Bellinger DA; Raymer RA; McCorquodale S; Ponder KP
    Blood; 2003 May; 101(10):3924-32. PubMed ID: 12531787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics.
    Van Raamsdonk JM; Ross CJ; Potter MA; Kurachi S; Kurachi K; Stafford DW; Chang PL
    J Lab Clin Med; 2002 Jan; 139(1):35-42. PubMed ID: 11873243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
    Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
    [No Abstract]   [Full Text] [Related]  

  • 27. An immunological method for detection of the carrier of hemophilia B.
    Matsuoka M; Ito M; Takahashi K; Sakuragawa N
    Thromb Haemost; 1976 Nov; 36(2):441-50. PubMed ID: 1036844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce.
    Herzog RW; Nichols TC; Su J; Zhang B; Sherman A; Merricks EP; Raymer R; Perrin GQ; Häger M; Wiinberg B; Daniell H
    Mol Ther; 2017 Feb; 25(2):512-522. PubMed ID: 28153098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alloantibodies in hemophilia B binding to multiple factor IX epitopes.
    Thompson AR
    Thromb Res; 1987 Apr; 46(1):169-74. PubMed ID: 2438804
    [No Abstract]   [Full Text] [Related]  

  • 30. Haemophilia B+ with inhibitor.
    Ludwig M; Schwaab R; Olek K; Brackmann HH; Egli H
    Thromb Haemost; 1988 Apr; 59(2):340. PubMed ID: 3388303
    [No Abstract]   [Full Text] [Related]  

  • 31. [Preparation of factor IX deficient plasma by immunoadsorption using monoclonal antibody (3A6) to factor IX and its application].
    Nishimura T; Ohkubo Y; Nishino M; Sakai T; Sawai J; Tanaka I; Takamiya O; Yoshioka A
    Rinsho Byori; 1986 Apr; 34(4):469-74. PubMed ID: 3528584
    [No Abstract]   [Full Text] [Related]  

  • 32. Sensitive solid phase enzyme immunoassay for factor IX antigen and classification of hemophilia B.
    Takamatsu J; Kamiya T; Ogata K; Sugihara T; Koie K; Kato K
    Haemostasis; 1983; 13(1):9-16. PubMed ID: 6341181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further studies on factor IX antigen in hemophilia B.
    Girolami A; Burul A; Cappellato G
    Blut; 1978 Oct; 37(4):215-7. PubMed ID: 81079
    [No Abstract]   [Full Text] [Related]  

  • 34. Hemophilia B variants.
    Yoshioka A
    Nihon Ketsueki Gakkai Zasshi; 1984 Dec; 47(8):1667-77. PubMed ID: 6532052
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic effects of hepatocyte transplantation on hemophilia B.
    Tatsumi K; Ohashi K; Shima M; Nakajima Y; Okano T; Yoshioka A
    Transplantation; 2008 Jul; 86(1):167-70. PubMed ID: 18622295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
    Bertina RM; van der Linden IK
    Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
    Thompson AR
    J Clin Invest; 1977 May; 59(5):900-10. PubMed ID: 856873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
    Russell KE; Olsen EH; Raymer RA; Merricks EP; Bellinger DA; Read MS; Rup BJ; Keith JC; McCarthy KP; Schaub RG; Nichols TC
    Blood; 2003 Dec; 102(13):4393-8. PubMed ID: 12933577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.
    Russell KE; Read MS; Bellinger DA; Leitermann K; Rup BJ; McCarthy KP; Keith JC; Khor SP; Schaub RG; Nichols TC
    Thromb Haemost; 2001 Mar; 85(3):445-9. PubMed ID: 11307812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent advances in hemophilia research].
    Ito S
    Rinsho Ketsueki; 1976 Jun; 17(6):580-9. PubMed ID: 787578
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.